GSK’s niraparib meets PFS goal in phase 3 PRIMA trial

GSK’s niraparib meets PFS goal in phase 3 PRIMA trial

Source: 
Pharmaceutical Business Review
snippet: 


GlaxoSmithKline (GSK) said that a phase 3 trial called PRIMA has demonstrated its polymerase (PARP) inhibitor Zejula (niraparib) to have significantly improved progression free survival (PFS) in women with first-line platinum responsive advanced ovarian cancer.